Retatrutide has no approved dose yet, so every chart is built from the Phase 3 trial doses: 2 mg to start, then 4, 6, 9 and 12 mg once a week. How many units that is depends only on your vial’s concentration. At 10 mg/mL (for example a 20 mg vial with 2 mL of bacteriostatic water) units = mg × 10: 2 mg = 20 units, 4 mg = 40 units, 9 mg = 90 units. At 5 mg/mL every number doubles, and 6 mg or more no longer fits in one syringe.

Open the retatrutide calculator → Enter your vial, water and dose to get exact units.

Dose chart: mg to units

Rule: units = mg ÷ mg/mL × 100 on a U-100 insulin syringe. Rows are the doses used in Eli Lilly’s TRIUMPH trials:

Weekly doseUnits at 5 mg/mLUnits at 10 mg/mLUnits at 15 mg/mLUnits at 20 mg/mL
2 mg402013.310
4 mg804026.720
6 mg120 **604030
9 mg180 **906045
12 mg240 **120 **8060

** More than a 100-unit (1 mL) syringe holds. At these doses a stronger concentration is used, which means less water per vial.

Reverse chart: units to mg

SyringeVolumemg at 5 mg/mLmg at 10 mg/mLmg at 15 mg/mLmg at 20 mg/mL
10 units0.1 mL0.5 mg1 mg1.5 mg2 mg
20 units0.2 mL1 mg2 mg3 mg4 mg
25 units0.25 mL1.25 mg2.5 mg3.75 mg5 mg
30 units0.3 mL1.5 mg3 mg4.5 mg6 mg
40 units0.4 mL2 mg4 mg6 mg8 mg
50 units0.5 mL2.5 mg5 mg7.5 mg10 mg
60 units0.6 mL3 mg6 mg9 mg12 mg
80 units0.8 mL4 mg8 mg12 mg16 mg
100 units1 mL5 mg10 mg15 mg20 mg

The trial schedule in units

In TRIUMPH-1, everyone started at 2 mg weekly and stepped up every four weeks until reaching their assigned dose: 4 mg after one step, 9 mg after 2 → 4 → 6, and 12 mg after 2 → 4 → 6 → 9. This is the fastest path to 12 mg, shown in units:

WeeksDoseUnits at 10 mg/mLUnits at 20 mg/mL
1–42 mg2010
5–84 mg4020
9–126 mg6030
13–169 mg9045
17+12 mg120 **60

This is how a trial was run, not a prescription. Lilly plans to file for US approval in the first quarter of 2027, so the approved schedule could differ.

How many doses one vial gives

This is the surprise for many people: at high doses, small vials run out almost immediately. Full weekly doses per vial:

Vial2 mg/week4 mg/week6 mg/week9 mg/week12 mg/week
10 mg52110
20 mg105321
30 mg157532

At 12 mg, a 10 mg vial is not even one dose. Mixing two vials to make one injection adds measuring error, so people on high doses use larger vials and stronger concentrations.

What the doses delivered in Phase 3

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and at least one weight-related condition, without diabetes. The two columns are two ways of counting: the first assumes people kept taking the drug; the second includes everyone, also those who stopped.

TRIUMPH-1, 80 weeksIf people stayed on treatmentEveryone randomized
4 mg−19.0%−17.6%
9 mg−25.9%−23.7%
12 mg−28.3%−25.0%
Placebo−2.2%−3.9%

In people with type 2 diabetes (TRIUMPH-2) weight loss was smaller, up to 20.8% at 12 mg, and in people with severe obesity and heart disease (TRIUMPH-3) up to 22.6%. Side effects rose with dose: at 12 mg, 42% had nausea and 25% vomiting (15% and 5% on placebo), and 11.3% stopped because of side effects. One newer finding is dysesthesia, unusual skin sensations such as tingling or burning, in about 12% on 9 or 12 mg versus 0.9% on placebo, mostly mild.

Before you use any chart

More on retatrutide: how much BAC water for 10 mg retatrutide, storing mixed retatrutide, and the retatrutide trial overview. Same charts for tirzepatide and semaglutide. For any other vial use the retatrutide calculator.

Comparing drugs? See the GLP-1 dosage chart with semaglutide, tirzepatide, retatrutide and more side by side.

Sources

  1. Eli Lilly via BioSpace. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, May 21, 2026).
  2. Eli Lilly. Retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3, July 23, 2026).